FOXP3+ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents
Figure 3
(a) Treg frequencies in Crohn’s disease patients (CD, ) and ulcerative colitis (UC, ) before and after anti-TNFα therapy; value by test for paired samples. (b) Treg frequencies in IBD patients according to the anti-TNFα treatment: infliximab (IFX, ); adalimumab (ADA, ); and certolizumab pegol (CZP, ); values by test for paired samples.
